Quart Barry D

SEC Form 4 insider trading activity

Quart Barry D has filed 7 SEC Form 4 filings (18 transaction rows) across 1 company, with disclosures dating back to 2025. 7 of those filings fall inside the rolling window. Most recent filing: Aug 21, 2026.

On the most recent filing, Quart Barry D is listed as Director at Kiniksa Pharmaceuticals International, plc. Inside the rolling window, Quart Barry D reported no open-market purchases and 8 open-market sales totaling $2.7M in KNSA. The largest disclosed transaction in the window is a sale of 20,129 KNSA shares on Dec 15, 2025, worth $836K.

Companies traded

Other insiders at KNSA

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$2.7M

reported sales (SEC code S)

Companies

1

in the rolling window

Source
KNSASale$656KApr 29SEC ↗
KNSASale$345KApr 8SEC ↗
KNSASale$5KFeb 12SEC ↗
KNSASale$121KFeb 12SEC ↗
KNSASale$37KFeb 4SEC ↗
KNSASale$567KFeb 4SEC ↗
KNSASale$117KFeb 4SEC ↗
KNSASale$836KDec 17SEC ↗
Showing 1–8 of 8
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Quart Barry D made?

Quart Barry D has filed 7 SEC Form 4 filings (18 transaction rows) across 1 company since 2025.

Which companies does Quart Barry D trade?

Quart Barry D has filed SEC Form 4 disclosures for 1 company, including KNSA.

When was Quart Barry D's most recent SEC Form 4 filing?

Quart Barry D's most recent SEC Form 4 filing on Tracefour is dated Aug 21, 2026.

What is Quart Barry D's total buy and sell value in the current window?

Inside the rolling retention window, Quart Barry D bought $0 and sold $2.7M based on SEC Form 4 filings.

What was Quart Barry D's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 20,129 KNSA shares on 2025-12-15, worth $836K, per SEC Form 4 filings.